Profile data is unavailable for this security.
About the company
Gartner, Inc. delivers actionable, objective insight to executives and their teams. The Company operates through three segments: Research, Conferences and Consulting. The Research segment delivers independent, objective insight to leaders across an enterprise through subscription services that include on-demand access to published research content, data and benchmarks, and direct access to a network of research experts located around the globe. Gartner Conferences are designed for information technology (IT) and business executives as well as decision makers looking to adapt and evolve their organizations through disruption and uncertainty, navigate risks and prioritize investments. The Consulting segment serves chief information officers and other senior executives to optimize technology investments and drive business impact. The Company also provides solutions for a range of IT-related priorities, including IT cost optimization, digital transformation, and IT sourcing optimization.
- Revenue in USD (TTM)5.97bn
- Net income in USD797.23m
- Incorporated1990
- Employees20.29k
- LocationGartner Inc56 Top Gallant Rd,P O Box 10212STAMFORD 06904-2212United StatesUSA
- Phone+1 (203) 964-0096
- Fax+1 (302) 636-5454
- Websitehttps://www.gartner.com/en
Mergers & acquisitions
| Acquired company | IT:NYQ since announced | Transaction value |
|---|---|---|
| KPC-Group SRO | 27.29% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals, Inc. | 2.00bn | -332.08m | 19.09bn | 2.10k | -- | -- | -- | 9.53 | -2.71 | -2.71 | 15.78 | -1.73 | 0.5552 | 2.85 | 11.67 | 953,969.10 | -9.20 | -26.56 | -11.86 | -32.77 | 83.95 | 83.66 | -16.58 | -94.26 | 3.07 | -1.37 | 1.27 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
| ICON PLC | 8.23bn | 683.12m | 26.21bn | 41.10k | 38.46 | 2.78 | 20.58 | 3.18 | 8.24 | 8.24 | 99.33 | 114.08 | 0.4795 | -- | 2.92 | 200,291.60 | 3.98 | 3.93 | 4.80 | 4.80 | 29.67 | 28.91 | 8.30 | 7.37 | -- | 3.48 | 0.2706 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
| Biogen Inc | 9.66bn | 1.17bn | 32.79bn | 7.57k | 28.14 | 2.16 | 19.32 | 3.39 | 8.00 | 8.00 | 66.40 | 104.48 | 0.3777 | 1.27 | 4.80 | 1,276,499.00 | 4.56 | 12.53 | 5.20 | 14.83 | 75.03 | 81.84 | 12.08 | 26.93 | 1.32 | 3.78 | 0.3007 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
| DuPont de Nemours Inc | 11.98bn | 404.00m | 32.84bn | 24.00k | 89.91 | 1.39 | 20.48 | 2.74 | 0.8736 | 0.8126 | 27.12 | 56.41 | 0.3036 | 3.37 | 4.99 | 499,208.30 | 1.12 | 0.3709 | 1.24 | 0.468 | 35.15 | 35.69 | 3.70 | 1.97 | 1.61 | 6.24 | 0.2446 | 414.03 | -7.29 | -11.79 | -51.19 | 11.24 | -30.66 | -20.59 |
| Gartner Inc | 5.97bn | 797.23m | 35.08bn | 20.29k | 44.98 | 49.22 | 35.40 | 5.88 | 10.05 | 10.05 | 75.24 | 9.18 | 0.7915 | -- | 3.80 | 295,054.30 | 10.57 | 8.24 | 19.95 | 14.76 | 67.72 | 67.55 | 13.35 | 12.20 | -- | 13.10 | 0.7738 | -- | 7.87 | 8.24 | 9.24 | 49.78 | -4.06 | -- |
| Iqvia Holdings Inc | 15.07bn | 1.36bn | 41.18bn | 87.00k | 30.84 | 6.49 | 16.51 | 2.73 | 7.33 | 7.33 | 81.34 | 34.82 | 0.5761 | -- | 4.64 | 173,206.90 | 5.19 | 3.24 | 6.93 | 4.07 | 35.03 | 34.32 | 9.01 | 6.03 | -- | 3.19 | 0.6809 | 0.00 | 3.98 | 7.55 | 24.47 | 43.39 | 7.17 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 8.64m | 11.10% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.41m | 5.67% |
| BAMCO, Inc.as of 31 Mar 2024 | 4.25m | 5.46% |
| Massachusetts Financial Services Co.as of 31 Mar 2024 | 3.25m | 4.18% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.19m | 4.10% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 2.35m | 3.02% |
| Geode Capital Management LLCas of 31 Mar 2024 | 1.78m | 2.29% |
| Polen Capital Management LLCas of 31 Mar 2024 | 1.75m | 2.25% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 1.70m | 2.18% |
| Principal Global Investors LLCas of 31 Mar 2024 | 1.56m | 2.00% |
